Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Publication year range
1.
Curr Issues Mol Biol ; 45(8): 6538-6549, 2023 Aug 07.
Article in English | MEDLINE | ID: mdl-37623231

ABSTRACT

Mycobacterium bovis BCG is the only vaccine against tuberculosis. The variable forms of cultivation throughout the years, before seed-lots were developed, allowed in vitro evolution of the original strain, generating a family of vaccines with different phenotypic and genotypic characteristics. Molecular studies revealed regions of difference (RDs) in the genomes of the various BCG strains. This work aims to characterize the gene pair rv3407-rv3408 (vapB47-vapC47), coding for a toxin-antitoxin system of the VapBC family, and to evaluate possible transcriptional effects due to the adjacent BCG Moreau-specific genomic deletion RD16. We show that these genes are co-transcribed in BCG strains Moreau and Pasteur, and that the inactivation of an upstream transcriptional repressor (Rv3405c) due to RD16 has a polar effect, leading to increased vapBC47 expression. Furthermore, we detect VapB47 DNA binding in vitro, dependent on a 5' vapB47 sequence that contributes to a palindrome, spanning the promoter and coding region. Our data shed light on the regulation of VapBC systems and on the impact of the BCG Moreau RD16 deletion in the expression of adjacent genes, contributing to a better understanding of BCG Moreau physiology.

2.
Mem Inst Oswaldo Cruz ; 117: e220164, 2023.
Article in English | MEDLINE | ID: mdl-36700581

ABSTRACT

Chagas disease is an enduring public health issue in many Latin American countries, receiving insufficient investment in research and development. Strategies for disease control and management currently lack efficient pharmaceuticals, commercial diagnostic kits with improved sensitivity, and vaccines. Genetic heterogeneity of Trypanosoma cruzi is a key aspect for novel drug design since pharmacological technologies rely on the degree of conservation of parasite target proteins. Therefore, there is a need to expand the knowledge regarding parasite genetics which, if fulfilled, could leverage Chagas disease research and development, and improve disease control strategies. The growing capacity of whole-genome sequencing technology and its adoption as disease surveillance routine may be key for solving this long-lasting problem.


Subject(s)
Chagas Disease , Trypanosoma cruzi , Humans , Chagas Disease/epidemiology , Trypanosoma cruzi/genetics , Genomics , Disease Management
3.
Front Cell Infect Microbiol ; 12: 898125, 2022.
Article in English | MEDLINE | ID: mdl-35909953

ABSTRACT

In Brazil, the production of KPC-type carbapenemases in Enterobacteriales is endemic, leading to widespread use of polymyxins. In the present study, 502 Klebsiella pneumoniae isolates were evaluated for resistance to polymyxins, their genetic determinants and clonality, in addition to the presence of carbapenem resistance genes and evaluation of antimicrobial resistance. Resistance to colistin (polymyxin E) was evaluated through initial selection on EMB agar containing 4% colistin sulfate, followed by Minimal Inhibitory Concentration (MIC) determination by broth microdilution. The susceptibility to 17 antimicrobials was assessed by disk diffusion. The presence of blaKPC, blaNDM and blaOXA-48-like carbapenemases was investigated by phenotypic methods and conventional PCR. Molecular typing was performed by PFGE and MLST. Allelic variants of the mcr gene were screened by PCR and chromosomal mutations in the pmrA, pmrB, phoP, phoQ and mgrB genes were investigated by sequencing. Our work showed a colistin resistance frequency of 29.5% (n = 148/502) in K. pneumoniae isolates. Colistin MICs from 4 to >128 µg/mL were identified (MIC50 = 64 µg/mL; MIC90 >128 µg/mL). All isolates were considered MDR, with the lowest resistance rates observed for amikacin (34.4%), and 19.6% of the isolates were resistant to all tested antimicrobials. The blaKPC gene was identified in 77% of the isolates, in consonance with the high rate of resistance to polymyxins related to its use as a therapeutic alternative. Through XbaI-PFGE, 51 pulsotypes were identified. MLST showed 21 STs, with ST437, ST258 and ST11 (CC11) being the most prevalent, and two new STs were determined: ST4868 and ST4869. The mcr-1 gene was identified in 3 K. pneumoniae isolates. Missense mutations in chromosomal genes were identified, as well as insertion sequences in mgrB. Furthermore, the identification of chromosomal mutations in K. pneumoniae isolates belonging from CC11 ensures its success as a high-risk epidemic clone in Brazil and worldwide.


Subject(s)
Anti-Bacterial Agents , Colistin , Drug Resistance, Bacterial , Klebsiella Infections , Klebsiella pneumoniae , beta-Lactamases , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Brazil , Colistin/pharmacology , Colistin/therapeutic use , Drug Resistance, Bacterial/drug effects , Drug Resistance, Bacterial/genetics , Humans , Klebsiella Infections/epidemiology , Klebsiella Infections/genetics , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Microbial Sensitivity Tests , Multilocus Sequence Typing , Polymyxins/adverse effects , Polymyxins/pharmacology , Polymyxins/therapeutic use , beta-Lactamases/genetics , beta-Lactamases/therapeutic use
4.
Mem. Inst. Oswaldo Cruz ; 117: e220164, 2022. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1422140

ABSTRACT

Chagas disease is an enduring public health issue in many Latin American countries, receiving insufficient investment in research and development. Strategies for disease control and management currently lack efficient pharmaceuticals, commercial diagnostic kits with improved sensitivity, and vaccines. Genetic heterogeneity of Trypanosoma cruzi is a key aspect for novel drug design since pharmacological technologies rely on the degree of conservation of parasite target proteins. Therefore, there is a need to expand the knowledge regarding parasite genetics which, if fulfilled, could leverage Chagas disease research and development, and improve disease control strategies. The growing capacity of whole-genome sequencing technology and its adoption as disease surveillance routine may be key for solving this long-lasting problem.

5.
Crit Rev Microbiol ; 47(4): 397-434, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33751923

ABSTRACT

Adaptation to environments with constant fluctuations imposes challenges that are only overcome with sophisticated strategies that allow bacteria to perceive environmental conditions and develop an appropriate response. The gastrointestinal environment is a complex ecosystem that is home to trillions of microorganisms. Termed microbiota, this microbial ensemble plays important roles in host health and provides colonization resistance against pathogens, although pathogens have evolved strategies to circumvent this barrier. Among the strategies used by bacteria to monitor their environment, one of the most important are the sensing and signalling machineries of two-component systems (TCSs), which play relevant roles in the behaviour of all bacteria. Salmonella enterica is no exception, and here we present our current understanding of how this important human pathogen uses TCSs as an integral part of its lifestyle. We describe important aspects of these systems, such as the stimuli and responses involved, the processes regulated, and their roles in virulence. We also dissect the genomic organization of histidine kinases and response regulators, as well as the input and output domains for each TCS. Lastly, we explore how these systems may be promising targets for the development of antivirulence therapeutics to combat antibiotic-resistant infections.


Subject(s)
Bacterial Proteins/metabolism , Gene Expression Regulation, Bacterial , Salmonella Infections/microbiology , Salmonella enterica/metabolism , Salmonella enterica/pathogenicity , Animals , Bacterial Proteins/genetics , Ecosystem , Humans , Salmonella enterica/genetics , Signal Transduction , Virulence
6.
Tuberculosis (Edinb) ; 113: 163-174, 2018 12.
Article in English | MEDLINE | ID: mdl-30514498

ABSTRACT

Tuberculosis patients taking second line drugs such as ethionamide (ETH) have often experienced previous treatment failure and usually have a complex history of disease and treatment that can span decades. Mutations in the ETH activating enzyme, EthA, confer resistance through undescribed mechanisms. To explore the impact of EthA mutations on ETH resistance, data from a total of 160 ETHR isolates was analysed. The most frequently mutated positions are within regions that display sequence conservation with the active site of OTEMO, another FAD-containing NADH-binding Baeyer-Villiger monooxygenase (BVMO), or with the sugar binding site of galectin-4N. Additionally, to look at a possible role of EthR on ETH resistance we purified an EthR mutant identified in a clinical isolate, F110L, and found it to bind the ethA-ethR intergenic region with higher affinity than the wild type regulator in gel shift assays. The ability of cyclic di-GMP to enhance DNA binding is maintained in the EthR mutant. To our knowledge, this is the first ETH resistance study that combines sequence and resistance data of clinical isolates with functional and structural information.


Subject(s)
Antitubercular Agents/therapeutic use , DNA, Bacterial/genetics , Drug Resistance, Bacterial/genetics , Ethionamide/therapeutic use , Genetic Loci , Mycobacterium tuberculosis/genetics , Tuberculosis/microbiology , Binding Sites , DNA, Bacterial/isolation & purification , Genotype , Humans , Mutation , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/isolation & purification , Oxidoreductases/genetics , Phenotype , Protein Binding , Protein Conformation , Repressor Proteins/genetics , Structure-Activity Relationship , Tuberculosis/diagnosis , Tuberculosis/drug therapy
7.
Salud(i)ciencia (Impresa) ; 19(6): 566-568, mar. 2013.
Article in Portuguese | LILACS | ID: lil-726451

ABSTRACT

Os testes bioquímicos realizados, o seqüenciamento de diferentes alvos genéticos e a construção de uma árvore concatenada, construída a través do método Neighbor-Joining, permitiram a identificação das cepas brasileiras como M. kyorinense.


Subject(s)
Brazil , Nontuberculous Mycobacteria/isolation & purification , Nontuberculous Mycobacteria/virology , Mycobacterium/isolation & purification , Mycobacterium/cytology , Mycobacterium/virology
8.
Int J Syst Evol Microbiol ; 63(Pt 7): 2583-2587, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23264503

ABSTRACT

Three isolates of a slow-growing, non-chromogenic mycobacterium were grown from three sputum samples of a patient from the north-eastern Ceará state in Brazil. Identification at species level could not be obtained with PCR restriction analysis of the hsp65 gene. In order to characterize the isolates we carried out phenotypic and genotypic tests. We sequenced the nearly complete 16S rRNA gene and obtained partial sequences of the hsp65 (encoding the hypervariable region of the 65 kDa heat-shock protein) and rpoB (encoding the beta-subunit of RNA polymerase) genes. The three isolates turned out to be identical and most closely related to the species Mycobacterium celatum and Mycobacterium kyorinense. The results, however, showed significant differences between these species and the isolates studied, which led us to consider them members of a novel species for which we propose the name Mycobacterium fragae. The type strain is HF8705(T) ( = Fiocruz-INCQS/CMRVS P4051(T) = DSM 45731(T)).


Subject(s)
Mycobacterium Infections/microbiology , Mycobacterium/classification , Phylogeny , Sputum/microbiology , Bacterial Proteins/genetics , Brazil , Chaperonin 60/genetics , DNA, Bacterial/genetics , Genes, Bacterial , Humans , Lung Diseases/microbiology , Molecular Sequence Data , Mycobacterium/genetics , Mycobacterium/isolation & purification , RNA, Ribosomal, 16S/genetics
9.
J Clin Microbiol ; 50(7): 2477-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22518856

ABSTRACT

In this article, the first isolation of Mycobacterium kyorinense specimens in Brazil is described. M. kyorinense is a recently identified species, with a few strains reported only in Japan. The Brazilian isolates were initially identified as Mycobacterium celatum by PCR restriction enzyme pattern analysis (PRA) with hsp65. However, biochemical tests indicated the same profile of M. kyorinense and distinguished them from M. celatum and Mycobacterium branderi. The sequencing of the hsp65, rpoB, and 16S rRNA genes allowed the accurate identification of isolates as M. kyorinense.


Subject(s)
Mycobacterium Infections/diagnosis , Mycobacterium Infections/microbiology , Mycobacterium/classification , Mycobacterium/isolation & purification , Bacterial Proteins/genetics , Brazil , Chaperonin 60/genetics , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , DNA-Directed RNA Polymerases/genetics , Humans , Molecular Sequence Data , Phylogeny , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL